Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BP1002 + Decitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BP1002||BP-1002|BP 1002||BCL2 inhibitor 26||BP1002 is a liposome containing an antisense oligonucleotide targeting BCL2 mRNA, which potentially decreases cancer cell viability (Cancer Res 2021;81(13_Suppl):Abstract nr 939).|
|Decitabine||Dacogen||5-aza-2-deoxycytidine||DNMT inhibitor (Pan) 5||Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05190471||Phase I||BP1002 + Decitabine BP1002||A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)||Recruiting||USA||0|